Vulcan Value Partners LLC grew its position in McKesson Co. (NYSE:MCK) by 7.8% during the 2nd quarter, HoldingsChannel reports. The fund owned 3,768,099 shares of the company’s stock after buying an additional 273,090 shares during the quarter. McKesson comprises about 3.9% of Vulcan Value Partners LLC’s holdings, making the stock its 9th biggest position. Vulcan Value Partners LLC’s holdings in McKesson were worth $502,664,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Unigestion Holding SA acquired a new stake in shares of McKesson in the second quarter valued at about $35,787,000. Strs Ohio lifted its stake in shares of McKesson by 4.9% in the second quarter. Strs Ohio now owns 363,323 shares of the company’s stock valued at $48,467,000 after purchasing an additional 17,057 shares during the period. Victory Capital Management Inc. lifted its stake in shares of McKesson by 284.7% in the second quarter. Victory Capital Management Inc. now owns 77,291 shares of the company’s stock valued at $10,311,000 after purchasing an additional 57,201 shares during the period. Martingale Asset Management L P lifted its stake in shares of McKesson by 38.6% in the second quarter. Martingale Asset Management L P now owns 6,443 shares of the company’s stock valued at $860,000 after purchasing an additional 1,796 shares during the period. Finally, Brandes Investment Partners LP lifted its stake in shares of McKesson by 0.5% in the second quarter. Brandes Investment Partners LP now owns 727,626 shares of the company’s stock valued at $97,066,000 after purchasing an additional 3,289 shares during the period. 88.58% of the stock is currently owned by institutional investors and hedge funds.
MCK traded up $0.63 during midday trading on Friday, reaching $126.13. 8,819 shares of the company’s stock were exchanged, compared to its average volume of 1,347,263. The company has a current ratio of 1.00, a quick ratio of 0.57 and a debt-to-equity ratio of 0.68. The stock has a market cap of $24.66 billion, a P/E ratio of 9.96, a PEG ratio of 1.32 and a beta of 1.25. McKesson Co. has a 1-year low of $122.49 and a 1-year high of $178.86.
McKesson (NYSE:MCK) last posted its quarterly earnings data on Thursday, July 26th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.89 by $0.01. The business had revenue of $52.61 billion during the quarter, compared to analyst estimates of $52.91 billion. McKesson had a negative net margin of 0.18% and a positive return on equity of 25.19%. The company’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.47 earnings per share. analysts forecast that McKesson Co. will post 13.33 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 1st. Stockholders of record on Tuesday, September 4th will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 1.24%. The ex-dividend date of this dividend is Friday, August 31st. This is a positive change from McKesson’s previous quarterly dividend of $0.34. McKesson’s payout ratio is currently 12.36%.
A number of brokerages have issued reports on MCK. Royal Bank of Canada cut their target price on shares of McKesson to $158.00 and set a “market perform” rating for the company in a research report on Friday, June 29th. ValuEngine cut shares of McKesson from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 2nd. Leerink Swann set a $160.00 target price on shares of McKesson and gave the stock a “market perform” rating in a research report on Tuesday, May 29th. Robert W. Baird cut shares of McKesson from an “outperform” rating to a “neutral” rating in a research report on Friday, July 20th. Finally, Standpoint Research upgraded shares of McKesson from a “hold” rating to a “buy” rating in a research report on Tuesday, July 10th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $154.30.
In other news, Director N Anthony Coles sold 1,350 shares of the business’s stock in a transaction that occurred on Friday, August 31st. The shares were sold at an average price of $128.69, for a total value of $173,731.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.87% of the company’s stock.
McKesson Company Profile
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Featured Story: What kind of dividend yield to CEF’s pay?
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.